CA2757828C - Methods and compositions for treating and preventing shiga toxin-producing escherichia coli infection - Google Patents

Methods and compositions for treating and preventing shiga toxin-producing escherichia coli infection Download PDF

Info

Publication number
CA2757828C
CA2757828C CA2757828A CA2757828A CA2757828C CA 2757828 C CA2757828 C CA 2757828C CA 2757828 A CA2757828 A CA 2757828A CA 2757828 A CA2757828 A CA 2757828A CA 2757828 C CA2757828 C CA 2757828C
Authority
CA
Canada
Prior art keywords
stec
fusion protein
seq
multiple epitope
epitope fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2757828A
Other languages
English (en)
French (fr)
Other versions
CA2757828A1 (en
Inventor
Andrew A. Potter
David Asper
Dragan Rogan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Saskatchewan
Original Assignee
University of Saskatchewan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Saskatchewan filed Critical University of Saskatchewan
Publication of CA2757828A1 publication Critical patent/CA2757828A1/en
Application granted granted Critical
Publication of CA2757828C publication Critical patent/CA2757828C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • C07K16/1232—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2757828A 2009-04-06 2010-04-06 Methods and compositions for treating and preventing shiga toxin-producing escherichia coli infection Active CA2757828C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21198909P 2009-04-06 2009-04-06
US61/211,989 2009-04-06
US21660809P 2009-05-19 2009-05-19
US61/216,608 2009-05-19
PCT/CA2010/000516 WO2010115278A1 (en) 2009-04-06 2010-04-06 Methods and compositions for treating and preventing shiga toxin-producing escherichia coli infection

Publications (2)

Publication Number Publication Date
CA2757828A1 CA2757828A1 (en) 2010-10-14
CA2757828C true CA2757828C (en) 2019-01-08

Family

ID=42935602

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2757828A Active CA2757828C (en) 2009-04-06 2010-04-06 Methods and compositions for treating and preventing shiga toxin-producing escherichia coli infection

Country Status (7)

Country Link
US (1) US8734811B2 (cg-RX-API-DMAC10.html)
EP (1) EP2417165B1 (cg-RX-API-DMAC10.html)
JP (2) JP2012522522A (cg-RX-API-DMAC10.html)
AU (1) AU2010234193B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI1014505B1 (cg-RX-API-DMAC10.html)
CA (1) CA2757828C (cg-RX-API-DMAC10.html)
WO (1) WO2010115278A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2014001126A1 (es) * 2014-04-29 2014-08-29 Univ Chile Composición farmacéutica útil como vacuna contra bacterias escherichia coli productoras de shigatoxinas (stec), que comprende al menos un antígeno o una proteína de membrana externa inmunogénica o proteína inmunogénica asociada y conservada en cepas stec.
CN114401730A (zh) * 2019-05-01 2022-04-26 因内特生物制品有限责任公司 免疫调节组合物和方法
JP2023501352A (ja) * 2019-11-08 2023-01-18 アイオーニス ファーマシューティカルズ， インコーポレーテッド Ｓｐｄｅｆ発現を低減するための化合物及び方法
WO2021242798A1 (en) * 2020-05-26 2021-12-02 Synlogic Operating Company, Inc. Surface display of proteins on recombinant bacteria and uses thereof
WO2024064200A2 (en) * 2022-09-20 2024-03-28 The Texas A&M University System Darpin-containing compositions and methods thereof
AR132724A1 (es) 2024-05-17 2025-07-23 Instituto Nac De Tecnologia Agropecuaria Inta Construcción de adn que codifica una proteína de fusión con al menos dos antígenos de escherichia coli enterohemorrágica, vectores, proteína de fusión, métodos de inmunización y vacunas

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055400A (en) 1986-11-26 1991-10-08 University Of Guelph Leukotoxin gene of pasteurella haemolytica
US4957739A (en) 1987-08-13 1990-09-18 Board Of Regents, The University Of Texas System Pharmaceutical compositions of a 105 kD P. Haemolytica derived antigen useful for treatment of Shipping Fever
CA2014033C (en) 1989-04-07 1993-02-09 Stephen D. Acres Compositions and treatments for pneumonia in animals
WO1991015237A1 (en) * 1990-04-05 1991-10-17 University Of Saskatchewan Compositions and treatments for pneumonia in animals
US5594107A (en) * 1990-08-22 1997-01-14 University Of Saskatchewan Chimeric protein comprising an RTX-family cytotoxin and interferon-2 or interferon
US5273889A (en) 1990-08-22 1993-12-28 University Of Saskatchewan Gamma-iterferon-leukotoxin gene fusions and uses thereof
US5238823A (en) 1990-08-22 1993-08-24 Veterinary Infectious Disease Organization Interleukin-2-leukotoxin gene fusions and uses thereof
US6797272B1 (en) 1991-10-16 2004-09-28 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
AU2699192A (en) 1991-10-16 1993-05-21 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
US5837268A (en) * 1991-10-16 1998-11-17 University Of Saskatchewan GnRH-leukotoxin chimeras
US5422110A (en) 1991-10-16 1995-06-06 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
US5723129A (en) 1991-10-16 1998-03-03 University Of Saskatchewan GnRH-leukotoxin chimeras
CA2252372C (en) 1996-04-23 2010-06-29 B. Brett Finlay Pathogenic escherichia coli associated protein
AU1137399A (en) 1997-11-12 1999-05-31 University Of British Columbia, The Hp90: host membrane receptor for pathogenic bacteria, encoded by the bacterial tir gene
BR9910905A (pt) * 1998-06-04 2001-02-13 Metamorphix Inc Vacinas de gnrh para suprimir comportamento reprodutivo em animais.
US6365723B1 (en) 1998-12-04 2002-04-02 Wisconsin Alumni Research Foundation Sequences of E. coli O157
AU2002218927B2 (en) 2001-01-04 2007-08-30 The University Of British Columbia Enterohemorrhagic Escherichia coli vaccine
WO2004050119A1 (en) * 2002-11-29 2004-06-17 Imperial College Innovations Limited Vaccine against enteropathogenic and enterohaemorragic escherichia coli
WO2007101337A1 (en) * 2006-03-06 2007-09-13 Bioniche Life Sciences Inc. Methods and compositions comprising bacterial type hi secreted proteins for mucosal immunization of animals
AU2007240614B2 (en) * 2006-04-20 2013-09-12 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Incorporated Methods and compositions based on Shiga toxin type 1 protein

Also Published As

Publication number Publication date
BRPI1014505B1 (pt) 2020-02-04
JP2016029049A (ja) 2016-03-03
BRPI1014505A2 (pt) 2016-04-05
US20120087939A1 (en) 2012-04-12
JP2012522522A (ja) 2012-09-27
EP2417165A1 (en) 2012-02-15
WO2010115278A8 (en) 2010-12-02
BRPI1014505A8 (pt) 2017-07-11
US8734811B2 (en) 2014-05-27
EP2417165A4 (en) 2013-02-13
AU2010234193B2 (en) 2015-08-20
CA2757828A1 (en) 2010-10-14
AU2010234193A1 (en) 2011-11-03
WO2010115278A1 (en) 2010-10-14
EP2417165B1 (en) 2016-05-25

Similar Documents

Publication Publication Date Title
Pruksakorn et al. Conserved T and B cell epitopes on the M protein of group A streptococci. Induction of bactericidal antibodies
CN1306956C (zh) 诱导功能活性抗体的脑膜炎球菌b抗原表位的分子模拟物
US8697856B2 (en) Plasmodium vivax hybrid circumsporozoite protein and vaccine
AU2002218927B2 (en) Enterohemorrhagic Escherichia coli vaccine
AU2010234193B2 (en) Methods and compositions for treating and preventing Shiga toxin-producing Escherichia coli infection
US20080009022A1 (en) Immunization of dairy cattle with chimeric gapC protein against streptococcus infection
EP0273116A2 (en) Gonococcal and meningococcal polypeptides, vaccines and diagnostics
US7169393B2 (en) Antigenic peptide fragments of VapA protein, and uses thereof
EP1694697B1 (en) Surface-located campylobacter jejuni polypeptides
US20160158333A1 (en) Methods for producing salmonella o-antigen capsules, compositions and uses thereof
Lun et al. Identification of a conserved cryptic epitope with cross-immunoreactivity in outer membrane protein K (OmpK) from Vibrio species
AU775996B2 (en) Cloning and expression of Haemophilus Somnus transferrin-binding proteins
JP2003515340A (ja) マイコプラズマ・ミコイデス亜種ミコイデスＳＣの抗原性タンパク質ＬｐｐＱ、その調製および使用
CN102659925A (zh) 用抗重组人zp4n和zp4c多抗鉴定的人卵透明带蛋白-4表位最小基序肽
AU2001252038B2 (en) Antigenic peptide fragments of vapa protein, and uses thereof
HK1097854B (en) Surface-located campylobacter jejuni polypeptides

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150327

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20251008

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20251106

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251107